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Abstract
Ikaros is a zinc finger transcriptional regulator encoded 
by the Ikzf1  gene. Ikaros displays crucial functions in 
the hematopoietic system and its loss of function has 
been linked to the development of lymphoid leukemia. 
In particular, Ikaros has been found in recent years to 
be a major tumor suppressor involved in human B-cell 
acute lymphoblastic leukemia. Its role in T-cell leu-
kemia, however, has been more controversial. While 
Ikaros deficiency appears to be very frequent in murine 
T-cell leukemias, loss of Ikaros appears to be rare in 
human T-cell acute lymphoblastic leukemia (T-ALL). 
We review here the evidence linking Ikaros to T-ALL in 
mouse and human systems.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Ikaros is a zinc finger transcriptional regulator that binds to 
specific DNA target sequences harboring the TGGGAA 
consensus motif[1,2]. How Ikaros regulates its target genes 
once bound to DNA is not entirely understood, and 
Ikaros has been found to activate or repress transcrip-
tion, depending on the target gene. Part of  its function 
may depend on the interaction of  Ikaros with chromatin 
remodeling complexes, which may be recruited by Ikaros 
to target sites[3,4]. A large number of  studies have shown 
that Ikaros is a key regulator within the hematopoietic 
system. Ikaros is crucial for controlling the development 
or the function of  almost all hematopoietic cell types (see 
other reviews in this issue). Mutations or polymorphisms 
that lead to reduced Ikaros function or expression have 
also been found to be a major genetic feature in human 
B-cell acute lymphoblastic leukemia (B-ALL)[5-8]. Loss of  
Ikaros also promotes the development of  T-cell lympho-
ma/leukemia in mice, which suggests that Ikaros acts as a 
tumor suppressor in T-cell acute lymphoblastic leukemia 
(T-ALL) and B-ALL. However, evidence linking Ikaros 
to human T-ALL has been elusive and sometimes contra-
dictory, and only recently has the involvement of  Ikaros 
in a small proportion of  human cases of  T-ALL become 
clear. We review below the role of  Ikaros in murine and 
human T-ALL.
TOPIC HIGHLIGHT
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ROLE OF IKAROS IN MOUSE T-ALL
Targeted Ikaros mutations lead to T-ALL
Ikaros function in mice has been addressed through sev-
eral mutant lines. The first mutant allele (Ikdn-) generated 
was a deletion of  exons 3 and 4, which encode the DNA 
binding domain (DBD)[9]. This mutation is dominant-
negative, because it allows the synthesis of  mutant pro-
teins that retain the C-terminal dimerization domain that 
can dimerize with, and inhibit, other Ikaros proteins or 
related proteins (such as Aiolos or Helios). Strikingly, 
heterozygous Ikdn+/- mice rapidly develop T-cell leuke-
mia, which provided the first genetic demonstration that 
Ikaros is a tumor suppressor in T cells[10]. A second dom-
inant-negative Ikaros allele, named IkPlastic, was isolated in 
an ENU mutagenesis screen. This allele harbors a point 
mutation in the third zinc finger of  the DBD. These 
mutant Ikaros proteins could therefore dimerize with 
their wild-type (WT) counterparts, but dimers fail to bind 
DNA[11]. Like Ikdn+/- mice, IkPlastic/+ mice develop T-ALL 
with a rapid onset. The third mutant allele (Ik-) was later 
generated by deleting the sequences that encode the 
C-terminal zinc fingers that are required for dimerization; 
this is considered a null mutation[12]. Clonal expansion of  
thymocyte populations occurs in these mice as early as 5 d 
after birth, which also suggests rapid onset of  leukemia. 
Finally, a hypomorphic allele, IkL, has been generated by 
Kirstetter et al[13], in which, the LacZ gene was targeted 
into the second exon. In these mice, in-frame transcripts 
between exons 1 and 3 are generated, which produce low 
amounts of  truncated Ikaros proteins (lacking the protein 
segment encoded by exon 2). All homozygote IkL/L mice 
develop T-cell lymphoma/leukemia in the thymus, with 
a median survival of  20 wk[14]. Thus, all mice that carry 
loss-of-function mutations in Ikaros develop T-cell leuke-
mia with high incidence, which highlights a strong tumor 
suppressor function for Ikaros in the T-cell lineage.
Spontaneous Ikaros mutations are frequent in mouse 
T-ALL
The prevalent role for Ikaros as a tumor suppressor in 
mouse T-cell leukemia has been underscored by stud-
ies that have identified frequent loss-of-function Ikaros 
mutations in murine thymic lymphoma induced by irra-
diation, mutagens or deficiency in DNA repair pathways 
(Table 1). Ikaros mutations have been detected in 20-85% 
of  the tumors, depending on the particular model and 
study. Two types of  defects have been observed: focal 
genomic deletions (mostly heterozygous) in the proximal 
part of  chromosome 11 where Ikaros is located; and 
point mutations in the coding regions that are missense 
mutations leading to amino acid changes in the DBD 
(and therefore are functionally similar to the Ikplastic mu-
tation), or mutations leading to premature stop codons 
that probably behave as null alleles. Ikaros has also been 
identified in several studies as a recurrent locus mutated 
by retroviral insertion, which cooperates with other pri-
mary oncogenic events such as activated Notch1 or K-ras 
proteins, or p19ARF deficiency (Table 1). These insertions 
appear to promote abnormal splicing and the synthesis 
of  aberrant, dominant-negative isoforms[15]. Together, 
these studies indicate that Ikaros is an important tumor 
suppressor gene whose inactivation can be triggered by 
several mechanisms in a variety of  murine T-cell leuke-
mias.
Function of Ikaros in murine T-cell leukemogenesis
The studies of  murine T-ALL models have implicated 
certain molecular pathways associated with the tumor 
suppressive activity of  Ikaros. Several reports have found 
a strong link between Ikaros deficiency and the activation 
of  the Notch pathway; the latter of  which plays a crucial 
role in human and murine T-ALL development. (1) High 
levels of  Notch target gene expression, as well as frequent 
selection of  activating mutations in the Notch1 gene, have 
been documented in T-cell lymphoma from the mouse 
models with germline Ikaros deficiencies[14,16,17]; (2) The 
selection of  secondary Ikaros mutations appears to be 
strongly associated with Notch1 mutations in mice[15,18-20]; 
and (3) Loss of  Ikaros function directly cooperates with 
Notch activation to promote leukemia[15]. At the molecu-
lar level, Ikaros appears to bind similar DNA sequences 
as RBP-J, the transcriptional mediator of  Notch signal-
ing[14,15], and Ikaros expression inhibits the proliferation 
of  leukemic cells and represses the expression of  Notch 
target genes such as Hes1[14,17]. Furthermore, Ikaros has 
been shown to silence some Notch target gene tran-
scription during T-cell differentiation, which suggests 
that increased sensitivity to Notch signals is crucial for 
promoting the outgrowth of  Notch-dependent leukemic 
cells[14,21,22]. Ikaros-mediated silencing of  Notch target 
gene expression appears to be particularly important at 
the DN4 stage of  T-cell differentiation; a stage at which 
Notch target genes are downregulated and Ikaros expres-
sion is strongly upregulated[21]. In this respect, Kleinmann 
and coworkers have shown at the single cell level that WT 
DN4 cells can no longer transcribe Hes1 in response to 
Notch signaling, and that this desensitization to Notch 
is crucially dependent on Ikaros function[21]. Indeed, the 
DN4 compartment is expanded in the thymus of  Ikaros-
deficient mice, which suggests that Ikaros-regulated cell 
proliferation in this compartment might be particularly 
relevant to tumor suppression[21,23].
Recently, three groups have addressed the in vivo role 
of  Notch signaling in Ikaros-deficient T-ALL, by deleting 
floxed RBP-J alleles in the T cells of  mice carrying vari-
ous Ikaros mutations. Chari et al[24] have studied the im-
pact of  RBP-J deletion on the expansion of  clonal popu-
lations in Ikaros null mice. Germline disruption of  RBP-J 
is lethal in utero, therefore, RBP-J was deleted specifically 
in DN4/DP (CD4+CD8+) thymocytes via CD4-Cre-
mediated deletion of  floxed RBP-J alleles. Surprisingly, 
clonal populations still emerge in RBP-J-deleted thymuses 
within the same time-frame as in RBP-J-proficient thy-
muses. However, these cells do not expand as efficiently 
as those from mice with undeleted RBP-J alleles, which 
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suggests that RBP-J (and thus Notch signaling) is re-
quired for the expansion but not the initiation of  Ikaros-
deficient T-ALL. These results, however, must be inter-
preted with caution, as RBP-J levels were not measured in 
the clonal populations, and transformation may occur in 
cells with partially deleted RBP-J alleles. Similarly, we de-
leted RBP-J in IkL/L mice with the CD4-Cre transgene[25]. 
In this case, RBP-J deletion significantly delays leukemia 
onset, and the leukemias that develop in these mice still 
carry the undeleted RBP-J alleles, which suggests a selec-
tion of  cells that express RBP-J. Finally, Gómez-del Arco 
et al[26] have deleted RBP-J in Ikdn+/- and Ik-/- mice using 
the CD2-Cre transgene, which deletes at the early thymic 
progenitor stage, and have also observed a significant 
decrease in leukemia incidence. Altogether, these results 
suggest an essential role for RBP-J and Notch signaling 
in the development of  Ikaros-deficient T-ALL.
We and Gómez-del Arco et al[26] have further ad-
dressed the role of  Notch1 in Ikaros-deficient thymo-
cytes by deleting floxed Notch1 alleles that correspond to 
3.5 kb of  the Notch1 promoter and exon 1[25]. Surprising-
ly, this deletion greatly accelerates, rather than delays, leu-
kemia development in both studies. Although the Notch1 
alleles are efficiently deleted in T cells, truncated Notch1 
proteins are generated from de novo transcripts that arise 
from cryptic intragenic promoters located between exons 
25 and 27, or upstream of  the deleted canonical pro-
moter. Activation of  the cryptic 3’ promoters is a direct 
consequence of  the deletion of  the canonical promoter, 
and an unexpected pro-oncogenic event[25]. Importantly, 
spontaneous Rag-mediated deletions of  the Notch1 pro-
moter region are common in murine T-ALL, including 
75% of  IkL/L leukemias[25,27,28]. Ikaros binds to both the 
5’ and the intragenic cryptic promoters in WT thymo-
cytes[25,26], which suggests that it plays a role in repressing 
their activity. If  so, Ikaros deficiency may cooperate with 
Notch1 promoter deletions in promoting the activation 
of  these alternative promoters. This hypothesis however 
awaits experimental demonstration.
Mouse studies have also implicated other pathways as-
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Table 1  Mutations of Ikaros in murine T-cell lymphomas
Study Model Alteration studied Type and frequency of Ikaros anomalies
Matsumoto et al[40], 1998 γ-irradiation (Balb/c-MSM F1 
hybrids)
Genome-wide LOH mapping 
(microsatellites)
Allelic loss in proximal chromosome 11 region: 
40% (8/20)
Okano et al[41], 1999 γ-irradiation (Balb/c-MSM F1 
hybrids)
LOH (polymorphic restriction site) Allelic loss: 54% (99/182)
Mutation analysis (SSCP and cDNA 
sequencing)
Homozygous deletions: 8/1081
Missense point mutations in DBD: 5/1081
Frame-shift or stop codon point mutations: 6/1081
Shimada et al[42], 2000 X-ray-induced thymic 
lymphomas
LOH (microsatellite mapping) Distal region of chromosome 11 containing the Ikzf1 
gene identified as a common deleted region in 50% 
of cases
Kakinuma et al[43], 2002 X-ray-induced thymic 
lymphomas
LOH 
RNA expression (RT-PCR)
Protein expression (Western blotting)
Point mutations 
LOH for Ikzf1 in 20/37 tumors
No or dn transcripts in 9/37 tumors (correlated 
with absence of Ikaros proteins or presence of dn 
Ikaros proteins)
Point mutations in 9/37 tumors (mostly zinc 
finger point mutations)2
Karlsson et al[44], 2002 Mutagen-induced thymic 
lymphoma 
Point mutation analysis (SSCA and 
sequencing)
Deletions (Southern)
Allelic loss (microsatellite)
8 DBD point mutations (8/104)
3 frame-shift mutations (3/104)
27% allelic loss (12/40)
3 homozygous deletions (3/68)
Beverly et al[15], 2003 Notch1-IC transgenic mice cooperating retroviral insertions 40% (synthesis of dn proteins)
López-Nieva et al[18], 2004 γ-irradiation (C57Bl6-Balb/c 
hybrids)
LOH (polymorphic restriction site) 42% (32/75) of LOH (1 homozygous deletion)
Point mutations (SSCP and sequencing) 1 missense mutation in DBD
Kakinuma et al[45], 2005 Mutagen-induced thymic 
lymphoma
LOH LOH: 2/27
Point mutations Point mutations: 5/27 (all in zn finger regions)
Kang et al[46], 2006 γ-irradiation (C57BL/6) CGH-array (BAC) Focal loss of chromosome 11: 20% (2/10)
Kakinuma et al[47], 2007 Mlh1-deficient mice (20 
spontaneous or radiation-
induced lymphomas)
Point mutation analysis Frame-shift point mutations: 85% (17/20)
Western blotting Lack of Ikaros protein: 75% (15/20)
Ohi et al[48], 2007 γ-irradiation (Balb/c-MSM 
F1 hybrids) 
LOH (polymorphic restriction site) 43% (15/35)
Yoshida et al[49], 2007 X-irradiation (C57Bl6-C3H 
F1 hybrids)
Karyotype Interstitial deletion of the proximal chromosome 
11: 27% (7/15)
Uren et al[19], 2008 p19ARF- and p53- deficient 
mice
Common retroviral insertions (CIS) 33/5103 (mostly in p19ARF-deficient mice; strong 
association with Notch1 activation
Dail et al[20], 2010 KrasG12D-induced thymic 
lymphomas
Retroviral insertional mutagenesis 30% (9/30) insertions into Ikaros gene leading to 
synthesis of dn proteins
1The 108 tested samples include the 99 with loss of heterozygosity (LOH); 2The tumors with point mutations are distinct from those exhibiting abnormal 
transcripts; 311 out of the 33 tumors had more than one hit in the Ikaros gene. CGH: Comparative genomic hybridization; SSCP: Single strand conformation 
polymorphism; SSCA: Single strand conformation analysis; dn: Dominant-negative; RT-PCR: Reverse transcription polymerase chain reaction.
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sociated with Ikaros deficiency. Uren et al[19] have compared 
cooperating retroviral insertion sites between p19ARF- and 
p53-deficient tumor models, and have found Ikaros in-
activation almost exclusively in p19ARF-deficient tumors, 
which suggests that loss of  Ikaros cooperates selectively 
with p19ARF inactivation but not with that of  p53. Interest-
ingly, Dumortier et al[14] also have detected a big decrease 
in p19ARF RNA expression in leukemic T cells from IkL/L 
mice. Furthermore, concomitant loss of  Ikaros and of  
p19ARF (encoded by the Cdkn2a gene) are hallmarks of  hu-
man Bcr-Abl-positive B-ALL, which suggests a conserved 
cooperating pathway in lymphoid malignancies[29].
Finally, Winandy et al[23] have addressed the role of  
T cell receptor (TCR) signaling in the development of  
T-cell leukemia in Ikdn+/- mice. Leukemia fails to develop 
when the Ikdn+/- mutation is introduced onto a Rag1-/- 
background, which indicates an important role for the 
pre-TCR/TCR in leukemia development. Intriguingly, 
deletion of  the α chain of  the TCR dramatically acceler-
ates leukemia progression, while ablation of  the TCR β 
chain promotes the clonal expansion of  cells expressing 
a γδTCR. These data indicate that signals from the pre-
TCR or the γδTCR may synergize with Ikaros deficiency 
to promote the outgrowth of  leukemic cells.
IKAROS IN HUMAN T-ALL
Evidence for Ikaros loss-of-function mutations in human 
T-ALL
The data demonstrating a clear role for Ikaros deficiency 
in the development of  murine T-cell leukemia have 
prompted investigation into the possibility of  a similar 
role in human T-ALL. A first study by Sun et al[30] has 
documented a strikingly high prevalence of  aberrant, 
dominant-negative Ikaros isoforms and their cognate 
transcripts in all 18 cases of  pediatric T-ALL studied. 
Furthermore, aberrant Ikaros proteins were localized in 
the cytoplasm of  the leukemic cells. This study therefore 
seemed to indicate that Ikaros plays an important role in 
human T-ALL.
Additional studies by other groups, however, have not 
confirmed these results. Ikaros status in human T-ALL 
has now been analyzed by seven other groups over the 
years, in a total of  134 samples. All together, these studies 
have revealed six cases with Ikaros anomalies, most often 
with genomic deletions (Table 2). Several of  these studies, 
however, have employed a limited set of  assays, and could 
thus have missed some defects. Recently, Marçais et al[31] 
have performed a multi-parameter analysis of  25 T-ALL 
cases from diverse genetic subtypes, investigating DNA 
(by CGH-array), RNA (by reverse transcription poly-
merase chain reaction and cDNA sequencing) and pro-
tein (by Western blotting and intracellular localization by 
immunofluorescence), and found only one case with de-
fective Ikaros. It appears therefore that Ikaros mutations 
that directly modify the gene and/or proteins are rela-
tively rare in human T-ALL, and occur in approximately 
5% of  cases. It is unclear why Sun et al[32] have found so 
many T-ALL cases with aberrant Ikaros. Given the results 
of  the other studies, it appears that the original study may 
have contained a systematic bias that led to the artefactual 
detection of  aberrant proteins and RNAs. It should be 
noted that, in another study by the same authors, similarly 
high frequencies of  Ikaros defects were found in B-ALL, 
which is also at odds with the current estimated frequency 
of  approximatively 30% for these leukemias.
In addition to direct genetic inactivation, Ikaros can 
also be inactivated at the functional level. This possibility 
was suggested by Marçais et al[31] in an intriguing case of  
Ikaros protein delocalization in leukemic cells (TL92) that 
had lost one of  its Ikaros alleles from a genomic dele-
tion. When analyzed by immunofluorescence, the Ikaros 
proteins synthesized from the remaining allele appeared 
to localize to a discrete cytoplasmic location; possibly 
the centrosome. Unfortunately, the limited material from 
this patient prevented further characterization of  the 
structure and mechanism involved in this delocalization. 
This observation suggests that delocalization of  Ikaros 
proteins might contribute to Ikaros inactivation in some 
T-ALL patients. It will thus be interesting to conduct a 
systematic investigation of  Ikaros localization in primary 
T-ALL cases.
It has also been suggested that Ikaros can be func-
tionally inactivated following sequestration by the CALM-
AF10 fusion protein in the cytoplasm, although this sce-
nario is mostly based on overexpression experiments in 
cell lines[33]. CALM-AF10 translocation occurs in a subset 
of  T-ALL, therefore, Ikaros localization in three primary 
T-ALL samples with the CALM-AF10 translocation was 
studied; no abnormality in Ikaros localization was ob-
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Table 2  Studies of Ikaros status in human T-cell acute lymphoblastic leukemia
Study No. of patients Methods used Cases with Ikaros abnormalities
Sun et al[30] 18 (pediatric) WB, EMSA, IF, RT-PCR 18/18
Nakase et al[50]   5 (adult) RT-PCR 0/5
Ruiz et al[51]   9 (pediatric) RT-PCR, WB 0/9
Maser et al[52] 24 (16 cell lines and 8 primary leukemias) CGH-array 2/24
Kuiper et al[53]   7 (unknown origin) CGH-array 0/7
Meleshko et al[54] 14 (pediatric) RT-PCR 1/14 (expression of dn Ik6 isoform)
Mullighan et al[6] 50 (unknown origin) CGH-array 2/50
Marçais et al[31] 25 (adult, pediatric) CGH-array, RT-PCR, WB, IF, cDNA sequencing 1/25
WB: Western blotting; EMSA: Electrophoretic mobility shift assay; IF: Immunofluorescence; RT-PCR: Reverse transcription polymerase chain reaction.
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served[31]. However, the expression and localization of  
CALM-AF10 was not analyzed, and further studies are 
thus required to assess the link between CALM-AF10 
and Ikaros in T-ALL.
Finally, Ikaros has been shown to be the target of  
secondary modifications that could alter its activity, such 
as phosphorylation and sumoylation[34,35], and the pos-
sible relevance of  altered post-translational modifications 
in suppressing Ikaros function in leukemic cells has been 
proposed[36]. The role of  indirect mechanisms that inacti-
vate Ikaros will be important to investigate in the future.
Is loss of Ikaros important in human T-ALL?
Despite the low prevalence, Ikaros loss of  function is 
clearly a recurrent anomaly in human T-ALL. Thus, 
Ikaros inactivation is unlikely to be a bystander defect and 
could play a causal role in disease progression in a subset 
of  T-ALL cases. T-ALL is a particularly heterogeneous 
disease with multiple subtypes, therefore, it will be im-
portant to determine if  loss of  Ikaros is associated with 
a specific class of  T-ALL, or if  Ikaros defects spread 
across molecular subtypes.
Given the strong link between Ikaros inactivation 
and Notch activation in murine T-ALL, a possible role 
for Ikaros loss in promoting Notch activation in human 
T-ALL is obviously of  interest. However, Notch target 
gene activation is not particularly elevated in the TL92 
case when compared with others[31]. Conversely, cases 
with high Notch target gene expression appear to ex-
press normal Ikaros[31]. Thus, Ikaros deficiency in human 
T-ALL may not be as strongly associated with Notch 
activation as it is in mice, and other pathways might be 
critical in human T-ALL. It will therefore be essential to 
achieve a better understanding of  how Ikaros suppresses 
leukemogenesis independent of  Notch. In this respect, 
insights gained from the role of  Ikaros mutations in 
B-ALL will be relevant, as Notch has so far not been im-
plicated in these leukemias.
CONCLUSION
The importance of  Ikaros as a tumor suppressor in mu-
rine T-cell leukemia has been known for about 15 years, 
but it is only becoming clear that Ikaros inactivation is 
a recurrent event in human T-ALL. Given that Ikaros is 
also a major tumor suppressor in human B-ALL[6,37,38], 
and that reduced Ikaros function dramatically accelerates 
B-cell leukemia development in mice[39], we hypothesize 
that Ikaros functions via common mechanisms to sup-
press B-ALL and T-ALL. Defining these mechanisms 
will be the central aim of  future research on the role of  
Ikaros in lymphoid malignancies.
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